Amarin Corp Plc (AMRN)

[Biobillionair]

A close look at '291..." Amarin's Generic and Epanova Patent"

Thank You Study and Zum for the find and drop box.

Claims interpreted by me are strictly my opinion and can not be used by AZN;) :
1) Composition treating Trigs, made of "about" 2200 mg of EPA (selected from a group ie. EE or FA or both), also contains not more than ABOUT 20% DHA by weight of all FA. Add on to statin, a key statement since Amarin found that on top of a Statin EPA lowers Trigs unexpectedly than just the statin alone, even if you doubled the statin dose...this is in the affidavit.

Very specific compare to the loose Lovaza Patent that protected it from generics for years.

2)&3) gonna reduce your Trigs by at least 10-15%

4) Reduces Non HDL C, important because many Lipid Societies have recommended ignoring LDL and Trigs and focus on Non HDL C...claiming it's a predictive value that incorporates both LDL & Trigs. (Europe)

5) Reduces Non HDL C about 5% (very significant and predictive for reducing CV disease risks)

6) Raise HDL-c, good cholesterol

7) 8) 9) phospholipase 2 reduction

10) Increase EPA blood levels by at least 200%, this is HUGE, it prevents engineering an EPA molecule (like some weird FA complex and string it alone as a new compound)

11) 12) 13) more on dose

14) Takes EPA blood levels up to 400%

15) composition contains about 20% DHA of total FA composition

16) treatment length at least 12 weeks

Actual claims wording, thanks Zum

https://dl.dropboxusercontent.com/u/57678878/13685291.pdf

----------------------

This is one of Amarins most important patents thus far. It destroys Epanova and severely limits generics from engineering a product that could even come close to Vascepa EPA blood levels. WS can try to ignore this, but come May, Epanova's PDUFA date, it'll be crystal clear.

Williams